Lupus nephritis treatment receives FDA approval

The U.S. Food and Drug Administration has approved the anti-CD20 monoclonal antibody obinutuzumab in patients with lupus nephritis, according to a news report from Biospace.

In the Phase 2 NOBILITY and Phase 3 REGENCY trials, researchers compared the safety and efficacy of obinutuzumab plus standard care or standard care alone in adult patients with lupus nephritis.

Compared with those in the standard care group, the patients in the combination treatment group experienced higher rates of complete renal response, reductions in anti-double-stranded DNA antibodies and proteinuria as well as less reliance on corticosteroids.

The researchers hope this approval of obinutuzumab, which has been approved for the treatment of certain hematologic malignancies since 2013, can help preserve kidney function and prevent progression to end-stage kidney disease in this patient population. The novel treatment is also currently being explored in patients with systemic lupus erythematosus and pediatric patients with lupus nephritis.

Read more: Biospace

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.